StockNews.com Begins Coverage on CEL-SCI (NYSE:CVM)

Stock analysts at StockNews.com began coverage on shares of CEL-SCI (NYSE:CVM) in a research note issued to investors on Wednesday. The brokerage set a “sell” rating on the stock.

CEL-SCI Price Performance

CEL-SCI stock opened at $0.33 on Wednesday. The firm has a market cap of $25.40 million, a PE ratio of -0.69 and a beta of 0.69. CEL-SCI has a 52-week low of $0.31 and a 52-week high of $2.50. The company has a quick ratio of 1.09, a current ratio of 1.07 and a debt-to-equity ratio of 0.66. The company’s 50 day moving average is $0.42 and its two-hundred day moving average is $0.73.

Institutional Investors Weigh In On CEL-SCI

A number of hedge funds and other institutional investors have recently modified their holdings of CVM. Plotkin Financial Advisors LLC acquired a new stake in shares of CEL-SCI in the 3rd quarter valued at $98,000. Geode Capital Management LLC raised its holdings in shares of CEL-SCI by 9.6% in the 3rd quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock valued at $650,000 after purchasing an additional 53,879 shares in the last quarter. Finally, Thoroughbred Financial Services LLC raised its holdings in shares of CEL-SCI by 40.1% in the 4th quarter. Thoroughbred Financial Services LLC now owns 191,661 shares of the company’s stock valued at $76,000 after purchasing an additional 54,900 shares in the last quarter. 12.08% of the stock is currently owned by institutional investors and hedge funds.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.